Oncolytics Biotech (ONCY) FCF Margin (2009 - 2020)

Oncolytics Biotech (ONCY) has reported FCF Margin for 7 consecutive years, with 17.16% the latest figure, recorded in Q3 2020.

• On a quarterly basis, FCF Margin rose 1957.0% year-over-year to 17.16% in Q3 2020; TTM through Sep 2020 was 16.34%, a 1351.0% decrease from a year earlier, with the FY2020 full-year figure at 54.15%, changed N/A from the prior year.
• FCF Margin was 17.16% for Q3 2020 at Oncolytics Biotech, down from 15.08% in the prior quarter.
• Over five years, FCF Margin peaked at 368.4% in Q2 2016 and troughed at 812.13% in Q2 2017.
• A 5-year average of 48.32% and a median of 12.35% in 2020 frame the typical range for FCF Margin.
• Across the five-year window, FCF Margin slumped 118054 bps in 2017 and soared 2354 bps in 2020, its largest moves.
• Over 5 years, FCF Margin stood at 368.4% in 2016, then tumbled by 320 bps to 812.13% in 2017, then soared by 104 bps to 32.07% in 2018, then tumbled by 215 bps to 36.73% in 2019, then jumped by 53 bps to 17.16% in 2020.
• The last three FCF Margin figures came in at 17.16% (Q3 2020), 15.08% (Q2 2020), and 9.63% (Q1 2020), per Business Quant data.